Full-Time

Specialty Account Manager

Referral Krystexxa, Rare Disease

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$139.5k - $164k/yr

+ Bonus + Sales-based Incentive Plan

Mid, Senior

Long Beach, CA, USA + 2 more

More locations: Santa Monica, CA, USA | Huntington Beach, CA, USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • Bachelor's Degree and 3 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
  • Or Associate degree and 6 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
  • Or High school diploma/GED and 8 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
Responsibilities
  • Representing Amgen's Rare Disease products to Primary Care/FP/GP/IM, Podiatry, and Orthopedic physicians and healthcare professionals
  • Establishing Biotech/Infusion product sales and increasing referrals for appropriate patients
  • Collaborate with 2-3 Specialty Account Managers in the Rheumatology and Nephrology sales teams
  • Develop a comprehensive and effective territory business plan
  • Promote Disease State awareness and value of product to target customers
  • Promote the identification of appropriate patient types for referral to treatment
  • Regularly communicate progress with SAM/ASD
  • Promote KRYSTEXXA® within approved labeling
  • Develop strong customer relationships
  • Consistently meet or exceed corporate sales goals
  • Communicate territory activity in an accurate and timely manner
  • Provide feedback to sales and commercial leadership
  • Adhere to Amgen’s compliance policies and guidelines
  • Successfully complete all Amgen training classes
  • Complete administrative duties in an accurate and timely fashion
  • Manage efforts within assigned promotional and operational budget
  • Maximize use of approved resources to achieve territory and account level goals
  • Attend medical congresses and society meetings as needed
  • Perform other tasks and responsibilities as requested by management
Desired Qualifications
  • Buy and bill experience and success preferred
  • Biologic/biotech sales and reimbursement experience preferred
  • Established customer relationships in primary care, podiatry and/or orthopedic markets required
  • Rheumatology and Nephrology therapeutic area experience preferred
  • Experience working in a team environment which successfully partners with all Commercial Operations functions
  • Strong organizational, analytical and computer skills required
  • Requires approximately 30% travel, including some overnight and weekend commitments
  • Proficient in Microsoft Office
  • Professional, proactive demeanor
  • Strong interpersonal skills
  • Excellent written and verbal communication skills

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen emphasizes biologic therapies and reinvests a large portion of its earnings back into R&D. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.